IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients.
Eur J Haematol
; 105(3): 326-334, 2020 Sep.
Article
em En
| MEDLINE
| ID: mdl-32421883
ABSTRACT
BACKGROUND:
In multiple myeloma (MM), impact of specific chromosomal translocations involving IgH (14q21 locus, including t(4;14), t(11;14), and t(14;16)) has been explored extensively. However, over 15% MM patients harboring IgH translocation with undefined partners have long been ignored.METHODS:
A prospective non-randomized cohort study with a total of 715 newly-diagnosed MM cases was conducted, 13.6% of whom were t(14;undefined) positive. The whole cohort was divided into four groups no IgH split (47.7%); t(14;undefined) (13.6%); t(11;14) (17.6%); and t(4;14) or t(14;16) group (21.1%).RESULTS:
Median OS for the four groups was 84.2, not reached (NR), 58.7, and 44.2 months, respectively, with P values for t(14;undefined) vs no IgH split, t(11;14), and t(4;14)/t(14;16) groups of 0.197, 0.022, and 0.001, respectively. In bortezomib-based group, the survival advantage gained by t(14;undefined) group was much more significant compared to t(11;14) and t(4;14)/t(14;16) groups. Importantly, t(14;undefined) turned out to be an independent predictive factor for longer OS of MM patients in multivariate analysis, especially in the context of bortezomib treatment. Similar results were also observed in the PUMCH external validation cohort.CONCLUSION:
Collectively, our data confirmed and externally validated the favorable prognosis of the t(14;undefined) groups, especially in the era of novel agents.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Translocação Genética
/
Cadeias Pesadas de Imunoglobulinas
/
Mieloma Múltiplo
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article